The estimated prevalence of the BRCA1 and BRCA2 pathogenic variant carriers is up to 0.3% in the general population, 3% in women with breast cancer, 6% in women with early onset breast cancer, 10% in women with ovarian cancer, and 20% in high‐risk families [2, 3]. The gene discussed is BRCA2; the disease is ovarian cancer.